NeoGenomics, Inc. Proceeds from Issuance or Sale of Equity
NeoGenomics, Inc. (NEO) reported Proceeds from Issuance or Sale of Equity of $160.77 million for the 9-month period ending 2019-09-30, per its 10-Q filed 2019-11-13.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOrSaleOfEquity · last filed 2019-11-13
- NeoGenomics, Inc. proceeds from issuance or sale of equity for the quarter ending 2019-09-30 was $0.00, a 100.00% decline year-over-year.
- NeoGenomics, Inc. proceeds from issuance or sale of equity for the quarter ending 2018-09-30 was $134.91M.
- NeoGenomics, Inc. proceeds from issuance or sale of equity for the quarter ending 2014-06-30 was $166.00K, a 23.88% increase year-over-year.
- NeoGenomics, Inc. proceeds from issuance or sale of equity for the quarter ending 2014-03-31 was $598.00K, a 93.48% decline year-over-year.
- NeoGenomics, Inc. proceeds from issuance or sale of equity for fiscal 2013 was $9.53M, a 1765.56% increase from fiscal 2012.
- NeoGenomics, Inc. proceeds from issuance or sale of equity for fiscal 2012 was $511.00K, a 85.32% decline from fiscal 2011.
- NeoGenomics, Inc. proceeds from issuance or sale of equity for fiscal 2011 was $3.48M, a 1834.44% increase from fiscal 2010.
- NeoGenomics, Inc. proceeds from issuance or sale of equity for fiscal 2010 was $180.00K.
| Period end | Proceeds from Issuance or Sale of Equity 3 month | Proceeds from Issuance or Sale of Equity 6 month | Proceeds from Issuance or Sale of Equity 9 month | Proceeds from Issuance or Sale of Equity 12 month |
|---|---|---|---|---|
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13 | $160.77M 10-Q · filed 2019-11-13 | ||
| 2019-06-30 | $160.77M 10-Q · filed 2019-08-07 | |||
| 2018-09-30 | $134.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13 | $134.91M 10-Q · filed 2019-11-13 | ||
| 2018-06-30 | $0.00 10-Q · filed 2019-08-07 | |||
| 2014-06-30 | $166.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-29 | $764.00K 10-Q · filed 2014-07-29 | $892.00K derived: sum of 3 quarters · filed 2014-07-29 | $996.00K derived: sum of 4 quarters · filed 2014-07-29 |
| 2014-03-31 | $598.00K 10-Q · filed 2014-05-12 | $726.00K derived: sum of 2 quarters · filed 2014-05-12 | $830.00K derived: sum of 3 quarters · filed 2014-05-12 | $964.00K derived: sum of 4 quarters · filed 2014-07-29 |
| 2013-12-31 | $128.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-24 | $232.00K derived: sum of 2 quarters · filed 2014-02-24 | $366.00K derived: sum of 3 quarters · filed 2014-07-29 | $9.53M 10-K · filed 2014-02-24 |
| 2013-09-30 | $104.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-30 | $238.00K derived: sum of 2 quarters · filed 2014-07-29 | $9.40M 10-Q · filed 2013-10-30 | $9.41M derived: sum of 4 quarters · filed 2014-07-29 |
| 2013-06-30 | $134.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-29 | $9.30M 10-Q · filed 2014-07-29 | $9.31M derived: sum of 3 quarters · filed 2014-07-29 | $9.43M derived: sum of 4 quarters · filed 2014-07-29 |
| 2013-03-31 | $9.17M 10-Q · filed 2014-05-12 | $9.18M derived: sum of 2 quarters · filed 2014-05-12 | $9.30M derived: sum of 3 quarters · filed 2014-05-12 | $9.60M derived: sum of 4 quarters · filed 2014-05-12 |
| 2012-12-31 | $8.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-24 | $130.00K derived: sum of 2 quarters · filed 2014-02-24 | $437.00K derived: sum of 3 quarters · filed 2014-02-24 | $511.00K 10-K · filed 2014-02-24 |
| 2012-09-30 | $122.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-30 | $429.00K derived: sum of 2 quarters · filed 2013-10-30 | $503.00K 10-Q · filed 2013-10-30 | $809.00K derived: sum of 4 quarters · filed 2014-02-24 |
| 2012-06-30 | $307.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-02 | $381.00K 10-Q · filed 2013-08-02 | $687.00K derived: sum of 3 quarters · filed 2014-02-24 | $773.00K derived: sum of 4 quarters · filed 2014-02-24 |
| 2012-03-31 | $74.00K 10-Q · filed 2013-05-13 | $380.00K derived: sum of 2 quarters · filed 2014-02-24 | $466.00K derived: sum of 3 quarters · filed 2014-02-24 | $538.00K derived: sum of 4 quarters · filed 2014-02-24 |
| 2011-12-31 | $306.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-24 | $392.00K derived: sum of 2 quarters · filed 2014-02-24 | $464.00K derived: sum of 3 quarters · filed 2014-02-24 | $3.48M 10-K · filed 2014-02-24 |
| 2011-09-30 | $86.00K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2012-11-05 | $158.00K derived: sum of 2 quarters · filed 2012-11-05 | $3.18M 10-Q · filed 2012-11-05 | $3.21M derived: sum of 4 quarters · filed 2012-11-05 |
| 2011-06-30 | $72.00K derived: 10-Q/A 6 month − 10-Q 3 month · filed 2012-08-15 | $3.09M 10-Q/A · filed 2012-08-15 | $3.12M derived: sum of 3 quarters · filed 2012-08-15 | $3.15M derived: sum of 4 quarters · filed 2012-08-15 |
| 2011-03-31 | $3.02M 10-Q · filed 2012-05-14 | $3.05M derived: sum of 2 quarters · filed 2012-05-14 | $3.08M derived: sum of 3 quarters · filed 2012-05-14 | |
| 2010-12-31 | $29.00K derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-12 | $64.00K derived: sum of 2 quarters · filed 2012-03-12 | $180.00K 10-K · filed 2012-03-12 | |
| 2010-09-30 | $35.00K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2011-10-25 | $151.00K 10-Q · filed 2011-10-25 | ||
| 2010-06-30 | $116.00K 10-Q/A · filed 2011-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 20/20 Biolabs, Inc. (AIDX) | United States | $0.005B |